Researchers Linked Galunisertib to OXPHOS Dependency
A new study has uncovered how leukemia cells adjust their metabolic requirements when treated with the drug Galunisertib.
Updated on Oct. 2, 2026 in Cancer
Scientists have identified a unique chromatin-to-mitochondrial dependency in pre-B leukemia cells exposed to Galunisertib. The research suggests that cells shift their metabolic reliance toward oxidative phosphorylation during treatment.
Why it matters
Understanding how cancer cells reorganize their dependencies upon drug exposure is crucial for overcoming treatment resistance. This finding highlights a specific metabolic state that could influence how future therapies are combined to improve efficacy.
A genome-wide screen revealed that oxidative phosphorylation was the only Hallmark gene set significantly enriched following treatment. This dependency architecture was mapped using NALM-6 pre-B leukemia cells.
The players
Galunisertib
This is a selective TGF-beta receptor I and ALK5 inhibitor currently being evaluated for its clinical efficacy in Phase II trials.
NALM-6
These pre-B leukemia cells served as the primary laboratory model for investigating cellular responses to drug exposure.
The details
Researchers employed CRANKS scoring, Hallmark gene set enrichment analysis, and STRING network mapping to cross-reference data with MitoCarta3.0 and MitoPathways3.0. The study determined that TCF4 acts as a high-confidence sensitizer, while the loss of iron-sulfur cluster biogenesis or mitochondrial translation can lead to resistance.
Timeline
October 2, 2026: The research article was officially published.
The Big Picture
This study follows a pattern set by the MitoCarta3.0 database by using its metabolic cataloging to classify cellular responses to drug treatment.
These findings provide a deeper understanding of how leukemia cells potentially evade treatment through metabolic adaptation. While the research is currently limited to laboratory models, it helps identify future pathways for targeting resistant cancer cells.
The takeaway
This study illustrates the complexity of cancer cell survival mechanisms when faced with targeted inhibitor therapies. Researchers aim to validate these findings with further metabolic testing to see how they might inform clinical strategies.
Further reading
For more information on current developments in oncological research, visit the Cancer section.
More information
View the complete peer-reviewed research article on the Nature portal.
Source note: This article includes information reported by Nature.
